TY - JOUR
T1 - Antiobesity and antihyperlipidaemic effects of Yan-Sheng-Yin in animals and humans
AU - Wu, Chi Han
AU - Pan, Chun Hsu
AU - Lee, Ching Kuo
AU - Sheu, Ming Jyh
AU - Liu, Fon Chang
AU - Wang, Guei Jane
AU - Wu, Chieh Hsi
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Yan-Sheng-Yin (YSY), a Chinese natural dietary supplement that promotes good health, is entirely composed of natural foods. Whether YSY is a potential adjuvant intervention for reducing hyperlipidaemia, atherogenesis, or obesity is unclear. This study evaluated the inhibitory effects and mechanisms of YSY for hyperlipidaemia, atherogenesis, and obesity. Experimental results showed that YSY reduced body weight, hyperlipidaemia, fatty liver, and atherogenesis in hyperlipidaemic mice. In addition, YSY promoted lipid metabolism by inducing adiponectin secretion and activation (phosphorylation) of 5' adenosine monophosphate-activated protein kinase (AMPK) and by suppressing the activation of acetyl-CoA carboxylase (ACC) and HMG-CoA reductase (HMGCR). Moreover, YSY inhibited adipocyte differentiation by suppressing peroxisome proliferator-activated receptor gamma (PPAR-γ) and CCAAT/enhancer-binding proteins (C/EBPs). Furthermore, the antihyperlipidaemic effect of YSY was observed in the clinical trial. Our findings suggest that YSY is an adjuvant intervention for treating and preventing hyperlipidaemia, atherogenesis, and obesity.
AB - Yan-Sheng-Yin (YSY), a Chinese natural dietary supplement that promotes good health, is entirely composed of natural foods. Whether YSY is a potential adjuvant intervention for reducing hyperlipidaemia, atherogenesis, or obesity is unclear. This study evaluated the inhibitory effects and mechanisms of YSY for hyperlipidaemia, atherogenesis, and obesity. Experimental results showed that YSY reduced body weight, hyperlipidaemia, fatty liver, and atherogenesis in hyperlipidaemic mice. In addition, YSY promoted lipid metabolism by inducing adiponectin secretion and activation (phosphorylation) of 5' adenosine monophosphate-activated protein kinase (AMPK) and by suppressing the activation of acetyl-CoA carboxylase (ACC) and HMG-CoA reductase (HMGCR). Moreover, YSY inhibited adipocyte differentiation by suppressing peroxisome proliferator-activated receptor gamma (PPAR-γ) and CCAAT/enhancer-binding proteins (C/EBPs). Furthermore, the antihyperlipidaemic effect of YSY was observed in the clinical trial. Our findings suggest that YSY is an adjuvant intervention for treating and preventing hyperlipidaemia, atherogenesis, and obesity.
KW - Adipocyte differentiation
KW - Atherogenesis
KW - Hyperlipidaemia
KW - Obesity
KW - Yan-Sheng-Yin
UR - http://www.scopus.com/inward/record.url?scp=84962907334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962907334&partnerID=8YFLogxK
U2 - 10.1016/j.jff.2016.04.004
DO - 10.1016/j.jff.2016.04.004
M3 - Article
AN - SCOPUS:84962907334
SN - 1756-4646
VL - 24
SP - 173
EP - 182
JO - Journal of Functional Foods
JF - Journal of Functional Foods
ER -
